ClinicalTrials.gg

Program

levacetylleucine

Its studies are mostly in Ataxia Telangiectasia · Spinocerebellar Ataxias · Niemann-Pick Disease, Type C, led by IntraBio.

Furthest: phase 3, since Dec 6, 20213 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
IntraBio33 open or runningphase 3since Dec 6, 2021Dec 6, 2021Dec 31, 2027phase 3 · NCT06673056

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 6, 2021First study: phase 3 study in Niemann-Pick Disease, Type CFirst studyNCT05163288 · 53 planned · United States, Australia, Czechia and more
  2. Oct 31, 2024Phase 3 study in Ataxia TelangiectasiaNCT06673056 · 60 enrolled · United States, Germany, Slovakia and more
  3. Oct 24, 2025Phase 3 study in Spinocerebellar AtaxiasNCT07221292 · 60 enrolled · United States, Austria, Germany and more

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Ataxia TelangiectasiaNCT06673056
  2. May 1, 2028Primary completion: phase 3 study in Spinocerebellar AtaxiasNCT07221292
  3. Jun 12, 2030Primary completion: phase 3 study in Niemann-Pick Disease, Type CNCT05163288

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07221292Spinocerebellar Ataxias · United States, Austria, Germany and more3Active, not recruitingMay 1, 202860
NCT06673056Ataxia Telangiectasia · United States, Germany, Slovakia and more3Active, not recruitingDec 31, 202760
NCT05163288Niemann-Pick Disease, Type C · United States, Australia, Czechia and more3RecruitingJun 12, 203053

How it is read

Names in the registry

  • “N-Acetyl-L-Leucine”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.